Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Astrazeneca Plc ADR (AZN)

Astrazeneca Plc ADR (AZN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
GSK's Specialty Medicines Unit on a Strong Footing: Here's Why

GSK plc’s GSK Specialty Medicines segment includes medicines that prevent and treat diseases like HIV, cancer, asthma and immune-inflammation diseases like lupus. Specialty Medicines now represents close...

AZN : 70.82 (+1.14%)
MRK : 83.71 (+2.88%)
GSK : 39.04 (+1.46%)
SNY : 48.83 (+1.35%)
The Zacks Analyst Blog Highlights T-Mobile US, AstraZeneca and Comcast

For Immediate ReleaseChicago, IL – July 9, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events...

TMUS : 232.31 (-1.55%)
CMCSA : 35.62 (-1.06%)
AZN : 70.82 (+1.14%)
Texas Just Passed Quantum Computing Legislation. How Should You Play IONQ Stock Here?

IonQ is a quantum computing stock poised to gain significant traction in a highly disruptive segment. Is IONQ stock a good investment right now?

QUBT : 19.14 (-1.09%)
ANSS : 366.87 (-0.01%)
AZN : 70.82 (+1.14%)
IONQ : 45.56 (+1.31%)
RGTI : 13.51 (+0.97%)
Top Analyst Reports for T-Mobile, AstraZeneca & Comcast

Tuesday, July 8, 2025The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including T-Mobile US, Inc....

TMUS : 232.31 (-1.55%)
UHS : 182.56 (+0.17%)
ETR : 81.46 (+0.65%)
CMCSA : 35.62 (-1.06%)
AZN : 70.82 (+1.14%)
ALGN : 200.48 (+2.56%)
AstraZeneca Boasts Strong Oncology Portfolio: Can It Sustain Growth?

AstraZeneca AZN is one of the leading drugmakers in the oncology space. Oncology sales (comprising around 41% of AstraZeneca‘s total revenues) rose 13% in the first quarter of 2025, generating $5.6...

AZN : 70.82 (+1.14%)
MRK : 83.71 (+2.88%)
PFE : 25.56 (-0.23%)
BMY : 47.66 (+1.32%)
Global Oncology Breakthroughs Being Fueled by Advancements in Clinical Trials and New Therapies

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:MBIO),(NASDAQ:VSTM),(NASDAQ:CRDF),(NASDAQ:AZN) EQNX::TICKER_END

ONCY : 1.2000 (-4.00%)
AZN : 70.82 (+1.14%)
ONC.TO : 1.61 (-5.29%)
VSTM : 4.81 (+2.12%)
CRDF : 4.08 (+3.55%)
MBIO : 3.11 (+16.92%)
Global Oncology Breakthroughs Being Fueled by Advancements in Clinical Trials and New Therapies

ONCY : 1.2000 (-4.00%)
AZN : 70.82 (+1.14%)
ONC.TO : 1.61 (-5.29%)
VSTM : 4.81 (+2.12%)
CRDF : 4.08 (+3.55%)
MBIO : 3.11 (+16.92%)
SMMT Stock Gains on Rumored Licensing Talks With AstraZeneca

Shares of clinical-stage company Summit Therapeutics SMMT rose nearly 9% on Thursday following a report issued by Bloomberg, which stated that pharma giant AstraZeneca AZN is in discussions with the company...

AZN : 70.82 (+1.14%)
MRK : 83.71 (+2.88%)
SMMT : 24.74 (+7.61%)
BMY : 47.66 (+1.32%)
Why AstraZeneca Stock Got Thumped on Thursday

AZN : 70.82 (+1.14%)
SMMT : 24.74 (+7.61%)
Does J&J's Innovative Medicine Unit Hold the Key to Q2 Sales Growth?

Johnson & Johnson JNJ, under its Innovative Medicine segment, markets several multi-million-dollar drugs that cover a broad range of areas such as neuroscience, cardiovascular and metabolism, immunology,...

AZN : 70.82 (+1.14%)
JNJ : 156.28 (+0.31%)
ABBV : 190.62 (+0.45%)
AMGN : 296.52 (-0.16%)

Barchart Exclusives

The Golden Rule of Grains: Why "Imaginary Fundamentals" Are Crushing Corn & Soybeans
In a "Markets Now" interview, Darin Newsom asserted that "fundamentals win in the end," explaining that grain markets face continued pressure from ample supply and declining export demand, while cattle markets remain strong due to tight supply and robust demand, attracting fund money. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar